The METIS clinical trial demonstrated a median time to intracranial progression of 21.9 months for patients treated with TTFields therapy and supportive care, compared to 11.3 months for those who received supportive care alone
Novocure will host a conference call with investors at 8:00 am EDT
ROOT, Switzerland–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the METIS Phase 3 clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression in adult patients treated with Tumor Treating Fields (TTFields) therapy and supportive care versus supportive care alone in the treatment of patients with 1-10 brain metastases from non-small cell lung cancer (NSCLC) after stereotactic radiosurgery (SRS).
The original text of this announcement, written in the source language, is the official version that is authentic. Translations are offered solely for the reader’s convenience and must refer to the original language text, which is the only legally valid one.
Contacts
Investors and media:
Ingrid Goldberg
[email protected]
[email protected]